• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

• share
• favorite_border

This special edition features presentations by MD Anderson researchers at the 2022 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches and novel targets to improve outcomes for patients with leukemias, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma and other hematologic cancers.

• share
• favorite_border

Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, has received a 2022 ASH Mentor Award from the American Society of Hematology in acknowledgement of his career-long commitment to mentoring.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features breast cancer presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS) focused on the combination of everolimus and hormone therapy, a new driver for brain metastases in inflammatory breast cancer, improving treatment for men with breast cancer, and a new understanding of the importance of HER2 expression for patients with early-stage triple-negative breast cancers.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist’s second multimillion-dollar commitment to MD Anderson in less than 10 years.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising targeted therapy combination for patients with relapsed/refractory acute myeloid leukemia (AML), a link between the gut microbiome and therapy-related neutropenic fever, a novel therapeutic target for immunotherapy-related colitis, a telementoring model for training providers on cervical cancer prevention in limited-resource areas, a new understanding of the prognostic value of RUNX1 mutations in AML, and insights into the effects of opioid use on the pain sensitivity pathway.

• share
• favorite_border

MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.

• share
• favorite_border

Eyal Gottlieb, Ph.D., has been named MD Anderson's vice president for Research. Gottlieb, an accomplished scientist and leader, will join the institution in January to uphold and expand the institution’s research excellence.

• share
• favorite_border

A team of researchers at The University of Texas MD Anderson Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.

• share
• favorite_border

This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.

• share
• favorite_border

Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Thousands are expected at MD Anderson’s Boot Walk to End Cancer® on Saturday, Nov. 5, as The University of Texas MD Anderson Cancer Center prepares for the in-person return of the seventh annual event in the Texas Medical Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

• share
• favorite_border

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced that the Timken Foundation of Canton, Ohio, has made a $5 million commitment to support the James P. Allison Institute at MD Anderson. The gift will support the recruitment of top minds from around the world to help realize the Allison Institute’s goals. By establishing a diverse and inclusive environment of scientists from many fields, the Allison Institute will drive exceptional research that integrates immunobiology across disciplines to develop a comprehensive understanding of the immune system.

• share
• favorite_border

In recognition of her trailblazing work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected to receive the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association of American Medical Colleges (AAMC).

• share
• favorite_border

Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The University of Texas MD Anderson Cancer Center reported in Nature.

• share
• favorite_border

Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery and receive standard radiation treatment with a low chance of disease recurrence, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. The Phase II trial results, published today in Lancet Oncology, evaluated the likelihood of breast cancer returning in patients who are in complete remission after receiving chemotherapy and radiation without surgery.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.

• share
• favorite_border

MD Anderson's James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022, featuring presentations and discussions on important topics in discovery and translational research that will drive the next wave of cancer breakthroughs. The event also includes a virtual poster session; interested researchers are encouraged to submit abstracts by October 24, 2022.

• share
• favorite_border

MD Anderson and ARTIDIS today announced a strategic alliance to investigate ARTIDIS nanotechnology platform as a treatment-optimization tool for patients with solid tumors.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to engineering natural killer (NK) cells with a second chimeric antigen receptor (CAR) to act as a logic gate, requiring two signals to eliminate a target cell. In preclinical studies, these next-generation CAR NK cells improved tumor specificity and enhanced anti-tumor activity by overcoming a process that contributes to NK cell dysfunction and tumor relapse.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression of graft-versus-host disease (GVHD) after antibiotic treatment of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and discovered that nutritional supplementation can prevent antibiotic-induced GVHD in preclinical models, according to a study published today in Cell.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight the importance of cancer research, to promote scientific collaboration and to reduce the global burden of cancer through improved prevention, early detection, treatment and survivorship strategies.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

• share
• favorite_border

MD Anderson and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.

• share
• favorite_border

MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.

• share
• favorite_border

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.

• share
• favorite_border

In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.

• share
• favorite_border

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.

• share
• favorite_border

MD Anderson and Virogin Biotech today announced a strategic collaboration to accelerate the development of oncolytic virus therapies for advanced cancers.

• share
• favorite_border

Swathi Arur, Ph.D., professor and deputy chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected as one of the 2022 Emerging Leaders in Health and Medicine Scholars by the National Academy of Medicine (NAM). Arur is the first MD Anderson faculty member to be appointed to this prestigious group since its creation in 2016.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.

• share
• favorite_border

MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.

• share
• favorite_border

The James P. Allison Institute at MD Anderson today announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.

• share
• favorite_border

The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include using a CRISPR screen to identify targets for improved chemotherapy responses, the potential of glutaminase inhibitors as novel treatments in renal cell carcinoma, engineered tumor-infiltrating lymphocytes to overcome immune suppression in ovarian cancer, oncolytic viruses to improve responses in glioblastoma, combination therapy options for KRAS/NRAS-mutant colorectal cancer, and a new treatment target for a subtype of myelodysplastic syndromes.

• share
• favorite_border

MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.

• share
• favorite_border

MD Anderson and TransCode announced a strategic alliance to advance TransCode's pipeline of RNA-targeted therapeutic and diagnostic candidates for oncology.

• share
• favorite_border

MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.

• share
• favorite_border

Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2022-23 “Best Hospitals” rankings.